Sign up to our newsletter Subscribe
Sign up to our newsletter Subscribe
This paper examines the views of US and European payers on the rapidly evolving fields of comparative effectiveness and relative effectiveness research. Recently published is a paper examining the views of payers in the United States and Europe on the…
This paper examines the views of US and European payers on the rapidly evolving fields of comparative effectiveness and relative effectiveness research.
Recently published is a paper examining the views of payers in the United States and Europe on the rapidly evolving fields of comparative effectiveness and relative effectiveness research. The paper, published in the International Journal of Technology Assessment in Health Care, is the result of a research collaboration between OHE and the Center for Medical Technology Policy (CMTP). The study was funded by a consortium of five pharmaceutical companies: Amgen, GSK, Lilly, Novartis and Sanofi.
The study included interviews with and a survey of ‘key informants’ (senior officials representing public and private payers, HTA bodies and Government agencies), structured around hypothetical cases resembling drugs expected to create policy challenges by 2020. The key informants considered that randomised controlled trials will remain essential for providing evidence of therapeutic effect but anticipated that more of these would have pragmatic designs. They also predicted greater use of observational studies and of policy levers such as conditional reimbursement or prior authorisation to manage diffusion of new drugs. The authors conclude by suggesting ways to engage payers, manufacturers and regulatory agencies in discussions regarding key methodological trade-offs.
Reference: Moloney, R., Mohr, P., Hawe, E., Shah, K., Garau, M. and Towse, A., 2015. Payer perspectives on future acceptability of comparative effectiveness and relative effectiveness research. International Journal of Technology Assessment in Health Care, 31(1-2), pp.90-98.
Download the full paper free-of-charge here.
Other papers resulting from this research collaboration between OHE and CMTP:
Towse, A., Garau, M., Mohr, P. and Messner, D.A., 2015. Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020. Journal of Comparative Effectiveness Research (Epub ahead of print). Download the full paper here.
Messner, D.A., Mohr, P. and Towse, A., 2015. Futurescapes: evidence expectations in the USA for comparative effectiveness research for drugs in 2020. Journal of Comparative Effectiveness Research (Epub ahead of print). Download the full paper here.
Messner, D.A., Towse, A., Mohr, P. and Garau, M., 2015. The future of comparative effectiveness and relative efficacy of drugs: an international perspective. Journal of Comparative Effectiveness Research (Epub ahead of print). Download the full paper here.
For more information on OHE’s research in this area, please contact Adrian Towse or Jorge Mestre-Ferrandiz.
An error has occurred, please try again later.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!